FDA OKs Sapien Valve As Pivotal Trial Control Prior To Marketing Approval
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences says FDA will support use of the firm's investigational Sapien transcatheter aortic heart valve as a control treatment in an upcoming trial of the firm’s next-generation Sapien XT.